AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27723271 — intervention group
Group type: COMPARATOR
Intervention: MTX monotherapy
Number of subjects: 588
Study 27723271 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib monotherapy
Number of subjects: 588
Study 26685691 — intervention group
Group type: EXPERIMENTAL
Intervention: HA injections (3 injections, one every 2 weeks)
Number of subjects: 165
Study 26685691 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-based rehabilitation (20 treatment sessions in a month)
Number of subjects: 165
Study 26685691 — intervention group
Group type: EXPERIMENTAL
Intervention: HA injections + Exercise-based rehabilitation (combined treatment)
Number of subjects: 165
Study 25445314 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse telephone support (DISPO ED)
Number of subjects: 500000
Study 25445314 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 500000
Study 24223328 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine spray (2 mg/kg)
Number of subjects: 120
Study 24223328 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine spray (0.05 mg/kg)
Number of subjects: 120
Study 24223328 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine spray (0.5 mg/kg)
Number of subjects: 120
Study 24223328 — intervention group
Group type: COMPARATOR
Intervention: Normal saline spray (8 puffs)
Number of subjects: 120
Study 19050634 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective diary intervention kept by nursing staff during ICU stay
Number of subjects: 36
Study 19050634 — intervention group
Group type: COMPARATOR
Intervention: Control group (no diary intervention)
Number of subjects: 36
Study 17961392 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride (2 times daily for 6 weeks, 1 capsule each time)
Number of subjects: 143
Study 17961392 — intervention group
Group type: COMPARATOR
Intervention: Glucosamine sulfate (3 times daily for 6 weeks, 2 capsules each time)
Number of subjects: 143
Study 15628826 — intervention group
Group type: EXPERIMENTAL
Intervention: rasagiline 1 mg
Number of subjects: 36
Study 15628826 — intervention group
Group type: EXPERIMENTAL
Intervention: rasagiline 5 mg
Number of subjects: 36
Study 15628826 — intervention group
Group type: EXPERIMENTAL
Intervention: rasagiline 2 mg
Number of subjects: 36
Study 15628826 — intervention group
Group type: EXPERIMENTAL
Intervention: rasagiline 10 mg
Number of subjects: 36
Study 15628826 — intervention group
Group type: EXPERIMENTAL
Intervention: rasagiline 20 mg
Number of subjects: 36
Study 15628826 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study 11265951 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 220
Study 11265951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 9554648 — intervention group
Group type: EXPERIMENTAL
Intervention: pHi <7.32
Number of subjects: 19
Study 9554648 — intervention group
Group type: EXPERIMENTAL
Intervention: pHi >= 7.32
Number of subjects: 19
Study 8302104 — intervention group
Group type: COMPARATOR
Intervention: Belief/Informational intervention group
Number of subjects: 301
Study 8302104 — intervention group
Group type: COMPARATOR
Intervention: Belief intervention
Number of subjects: 301
Study 8302104 — intervention group
Group type: COMPARATOR
Intervention: Informational intervention
Number of subjects: 301
Study 8302104 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 301
Study 2657547 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural administration of epinephrine-morphine-bupivacaine drug combination
Number of subjects: 50
Study 31748836 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative oxygen therapy
Number of subjects: 251
Study 31748836 — intervention group
Group type: COMPARATOR
Intervention: Usual oxygen therapy
Number of subjects: 251
Study 31227278 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily subcutaneous 0.20-μg Teriparatide injection for 8 weeks
Number of subjects: 16
Study 31227278 — intervention group
Group type: COMPARATOR
Intervention: No treatment for 8 weeks
Number of subjects: 16
Study 31227278 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily subcutaneous 0.20-μg Teriparatide injection for 8 weeks (after 8 weeks of no treatment)
Number of subjects: 16
Study 31227278 — intervention group
Group type: COMPARATOR
Intervention: No treatment for 8 weeks (followed by Teriparatide treatment)
Number of subjects: 16
Study 27665293 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 112
Study 27665293 — intervention group
Group type: COMPARATOR
Intervention: Neurofeedback (NFB)
Number of subjects: 112
Study 27665293 — intervention group
Group type: COMPARATOR
Intervention: Physical Activity (PA)
Number of subjects: 112
Study 27665293 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (NFB, MPH, PA)
Number of subjects: 112
Study 25710943 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 28
Study 25710943 — intervention group
Group type: COMPARATOR
Intervention: Control (Con)
Number of subjects: 28
Study 23520220 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) intervention for anger management, delivered over 12 weeks
Number of subjects: 179
Study 23520220 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 179
Study 23520220 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) intervention for anger management
Number of subjects: 179
Study 21122818 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 12
Study 21122818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 19841527 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg/d
Number of subjects: 80
Study 19841527 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 15 mg/d
Number of subjects: 80
Study 19841527 — intervention group
Group type: COMPARATOR
Intervention: Routine folic acid supplementation 10 mg/d
Number of subjects: 80
Study 17530984 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) at 20, 27, or 34 Hz for 4 weeks
Number of subjects: 28
Study 17530984 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) at long muscle lengths
Number of subjects: 28
Study 17530984 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) at short muscle lengths
Number of subjects: 28
Study 17530984 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) at lower frequencies
Number of subjects: 28
Study 17530984 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training
Number of subjects: 28
Study 17530984 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration frequency and muscle length during vibration
Number of subjects: 28
Study 16260422 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole therapy for Graves' hyperthyroidism
Number of subjects: 24
Study 16260422 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term experimental hyperthyroidism in healthy subjects
Number of subjects: 24
Study 16260422 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine substitution in hypothyroid patients
Number of subjects: 24
Study 11821452 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC)
Number of subjects: 60
Study 9799029 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation (64 mmol/day of K as slow-release KCl tablets)
Number of subjects: 55
Study 9799029 — intervention group
Group type: COMPARATOR
Intervention: Control period (no potassium supplementation)
Number of subjects: 55
Study 9799029 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation
Number of subjects: 55
Study 7900700 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 10(6) IU/day of rIL-2
Number of subjects: 9
Study 7900700 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 x 10(6) IU/day of rIL-2
Number of subjects: 9
Study 7900700 — intervention group
Group type: EXPERIMENTAL
Intervention: 27 x 10(6) IU/day of rIL-2
Number of subjects: 9
Study 7900700 — intervention group
Group type: COMPARATOR
Intervention: Calmette-Guérin bacillus locoregional instillation
Number of subjects: 9
Study 2793707 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine (A) 75 mg po
Number of subjects: 8
Study 2793707 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 8
Study 2793707 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine (A)
Number of subjects: 8
Study 367713 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenbufen 600 mg daily
Number of subjects: 20
Study 367713 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 75 mg daily
Number of subjects: 20
Study 367713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31880246 — intervention group
Group type: EXPERIMENTAL
Intervention: β-D-Mannuronic Acid (M2000)
Number of subjects: 0
Study 31677528 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-compassion intervention
Number of subjects: 119
Study 31677528 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring intervention
Number of subjects: 119
Study 29297443 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT) started at Month 1 after screening for active TB.
Number of subjects: 1030
Study 29297443 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned).
Number of subjects: 1030
Study 24524384 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise targeting back and core muscles, two times per week for 24 weeks
Number of subjects: 96
Study 24524384 — intervention group
Group type: COMPARATOR
Intervention: Control group continued their usual fitness regimen
Number of subjects: 96
Study 23729925 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 consecutive nights of sleep restriction (6.5 hours in bed Monday‐Friday)
Number of subjects: 41
Study 23729925 — intervention group
Group type: COMPARATOR
Intervention: Healthy sleep duration (10 hours in bed)
Number of subjects: 41
Study 21302033 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem alone (5 mg)
Number of subjects: 20
Study 21302033 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem after pre-treatment with ciprofloxacin (5 mg zolpidem + 500 mg ciprofloxacin)
Number of subjects: 20
Study 20027405 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg etoricoxib
Number of subjects: 78
Study 20027405 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone
Number of subjects: 78
Study 20027405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 16483659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Number of subjects: 64
Study 16483659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 64
Study 16483659 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 64
Study 15208594 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B (200 microL per nostril, 3 mg/mL, 4 times daily for 8 weeks)
Number of subjects: 78
Study 15208594 — intervention group
Group type: COMPARATOR
Intervention: Control (saline nasal spray, 4 times daily for 8 weeks)
Number of subjects: 78
Study 15208594 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 78
Study 15208594 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 78
Study 10096692 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE response to Timothy grass pollen measured by the RAST test
Number of subjects: 234
Study 10096692 — intervention group
Group type: COMPARATOR
Intervention: Broad and narrow definitions of SRA phenotypes
Number of subjects: 234
Study 7495975 — intervention group
Group type: EXPERIMENTAL
Intervention: High-purity factor VIII preparations (ion-exchange S/D step)
Number of subjects: 0
Study 7495975 — intervention group
Group type: COMPARATOR
Intervention: Monoclonal antibody factor VIII preparations
Number of subjects: 0
Study 2139833 — intervention group
Group type: EXPERIMENTAL
Intervention: tiadenol
Number of subjects: 40
Study 2139833 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin
Number of subjects: 40
Study 6990858 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cholegraphy (IVC)
Number of subjects: 67
Study 6990858 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholecystography (OCC)
Number of subjects: 67
Study 6990858 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonography (US)
Number of subjects: 67
Study 31394601 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment
Number of subjects: 71
Study 31394601 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 71
Study 27785586 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial removable dental prosthesis (PRDP)
Number of subjects: 91
Study 27785586 — intervention group
Group type: COMPARATOR
Intervention: Shortened dental arch (SDA) concept
Number of subjects: 91
Study 24811226 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NG) dermal patch
Number of subjects: 0
Study 24811226 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 0
Study 22370697 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based smoking cessation intervention (PFH-2)
Number of subjects: 2005
Study 20849685 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated sensitisation using clinical vignettes at 1, 3, and 5 months
Number of subjects: 1138
Study 20849685 — intervention group
Group type: COMPARATOR
Intervention: No sensitisation
Number of subjects: 1138
Study 17992715 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula containing LCPUFA (arachidonic and docosahexaenoic) (group A, n = 50)
Number of subjects: 104
Study 17992715 — intervention group
Group type: COMPARATOR
Intervention: LCPUFA‐free formula (group B, n = 54)
Number of subjects: 104
Study 16304259 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) for 1 year
Number of subjects: 42
Study 16304259 — intervention group
Group type: COMPARATOR
Intervention: Control group (very low load training)
Number of subjects: 42
Study 12085255 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin use (three or more times per week for at least 6 months)
Number of subjects: 81
Study 12085255 — intervention group
Group type: COMPARATOR
Intervention: No aspirin use
Number of subjects: 81
Study 10213219 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial measurements of PSA, hemoglobin, and weight
Number of subjects: 348
Study 10213219 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic score based on PSA, hemoglobin, and weight
Number of subjects: 348
Study 7608257 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 1 IU/m2.day
Number of subjects: 46
Study 7608257 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 2 IU/m2.day
Number of subjects: 46
Study 7608257 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 3 IU/m2.day
Number of subjects: 46
Study 7608257 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 0.33 IU/m2.day
Number of subjects: 46
Study 7608257 — intervention group
Group type: EXPERIMENTAL
Intervention: GH < 0.67 IU/m2.day
Number of subjects: 46
Study 7608257 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 1.10 IU/m2.day
Number of subjects: 46
Study 7608257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 2132273 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% oral benzydamine spray applied six times per day (four sprays per application) for five days
Number of subjects: 27
Study 2132273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 7398470 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin/Bacitracin
Number of subjects: 0
Study 7398470 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 0
Study 7398470 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Neomycin/Bacitracin and Clindamycin
Number of subjects: 0
Study 30296614 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental sensorimotor incongruence (SMI) induced via distorting visual feedback during movement
Number of subjects: 66
Study 30296614 — intervention group
Group type: COMPARATOR
Intervention: Static visual feedback
Number of subjects: 66
Study 28809724 — intervention group
Group type: EXPERIMENTAL
Intervention: QuikClot Radial pad (30 min compression)
Number of subjects: 30
Study 28809724 — intervention group
Group type: EXPERIMENTAL
Intervention: QuikClot Radial pad (60 min compression)
Number of subjects: 30
Study 28809724 — intervention group
Group type: COMPARATOR
Intervention: TR Band (mechanical compression)
Number of subjects: 30
Study 26418025 — intervention group
Group type: EXPERIMENTAL
Intervention: PFO closure
Number of subjects: 40
Study 26418025 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PFO closure)
Number of subjects: 40
Study 24494277 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with auricular point sticking therapy (group A)
Number of subjects: 100
Study 24494277 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene oral administration (group B)
Number of subjects: 100
Study 22045822 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal immunochemical test (FIT)
Number of subjects: 11632
Study 22045822 — intervention group
Group type: COMPARATOR
Intervention: Guaiac faecal occult blood test (gFOBT)
Number of subjects: 11632
Study 22045822 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall test uptake (comparing FIT and gFOBT)
Number of subjects: 11632
Study 19270248 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic‐Focused Psychodynamic Psychotherapy (PFPP)
Number of subjects: 0
Study 19270248 — intervention group
Group type: COMPARATOR
Intervention: Applied Relaxation Training (ART)
Number of subjects: 0
Study 17218230 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 800 mg daily for 6 months
Number of subjects: 88
Study 17218230 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 88
Study 16503940 — intervention group
Group type: EXPERIMENTAL
Intervention: Birch bark ointment only
Number of subjects: 28
Study 16503940 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with cryotherapy and birch bark ointment
Number of subjects: 28
Study 12717217 — intervention group
Group type: EXPERIMENTAL
Intervention: WOFIE protocol (immunosuppression stopped for 72 hr posttransplant)
Number of subjects: 30
Study 12717217 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard immunosuppression without WOFIE)
Number of subjects: 30
Study 10733053 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-based, computerized intervention
Number of subjects: 45
Study 10733053 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 8963651 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg melatonin administered orally 60 min prior to the light pulse
Number of subjects: 6
Study 8963651 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered orally 60 min prior to the light pulse
Number of subjects: 6
Study 1854430 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy using the alpha-fraction of D. pteronyssinus
Number of subjects: 0
Study 1854430 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 0
Study 6178347 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with high-molecular-weight dextran and adrenaline
Number of subjects: 40
Study 6178347 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with high-molecular-weight dextran without adrenaline
Number of subjects: 40
Study 6178347 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine with saline
Number of subjects: 40
Study 30121721 — intervention group
Group type: EXPERIMENTAL
Intervention: LED phototherapy (180 mW, 22 s, 4 J, 8 J/cm2, 0.36 W/cm2, spot of 0.5 cm2, spot diameter 0.8 cm)
Number of subjects: 40
Study 30121721 — intervention group
Group type: COMPARATOR
Intervention: Control group (not irradiated)
Number of subjects: 40
Study 28802882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.05 mg/kg)
Number of subjects: 4
Study 28802882 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 4
Study 28802882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.05 mg/kg) in opioid-naive subjects
Number of subjects: 4
Study 28802882 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo in chronic opioid users
Number of subjects: 4
Study 26007637 — intervention group
Group type: EXPERIMENTAL
Intervention: Kv7.2(A294V) mutation
Number of subjects: 7
Study 26007637 — intervention group
Group type: EXPERIMENTAL
Intervention: Kv7.2(A294V) with Kv7.3 subunit
Number of subjects: 7
Study 26007637 — intervention group
Group type: EXPERIMENTAL
Intervention: Kv7.2(A294V)/Kv7.2/Kv7.3 configuration
Number of subjects: 7
Study 26007637 — intervention group
Group type: COMPARATOR
Intervention: Kv7.2(A294G) mutation
Number of subjects: 7
Study 26007637 — intervention group
Group type: EXPERIMENTAL
Intervention: p.A294V mutation in neurons
Number of subjects: 7
Study 26007637 — intervention group
Group type: COMPARATOR
Intervention: p.A294G mutation in neurons
Number of subjects: 7
Study 23846316 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 100/25 μg once daily
Number of subjects: 806
Study 23846316 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate/salmeterol (FP/SAL) 250/50 μg bid
Number of subjects: 806
Study 23846316 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 806
Study 21672495 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum electroacupuncture (12 sessions of 30 minutes each over 6 to 8 weeks)
Number of subjects: 53
Study 21672495 — intervention group
Group type: COMPARATOR
Intervention: Control acupuncture (needling at nonchannel scalp points with sham electrostimulation, 12 sessions of 30 minutes each over 6 to 8 weeks)
Number of subjects: 53
Study 19843784 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lidocaine
Number of subjects: 65
Study 19843784 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 65
Study 17202945 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 150